Nasdaq Moln News Today

Molecular Partners AG (NASDAQ:MOLN – Get Free Report) shares were up 5.5% on Thursday . The company traded as high as $4.66 and last traded at $4.66. Approximately 2,515 shares traded hands during mid-day trading, a decline of 90% from the average daily volume of 26,157 shares. The stock had previously closed at $4.41. Analyst […]

Tetra-specific T-cell engager MP0533 for patients with r/r AML and AML/MDS on track to deliver expanded clinical phase 1/2a data in H1 2024Progress of...

Presentation will highlight versatility of DARPin designs in enabling conditional activation of the immune system to fight tumors, addressing toxicities...

Molecular Partners (NASDAQ:MOLN – Get Free Report) is one of 286 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it weigh in compared to its competitors? We will compare Molecular Partners to related companies based on the strength of its earnings, valuation, analyst recommendations, risk, institutional ownership, profitability and dividends. Volatility […]

New preclinical RDT data show that DARPins can be engineered to increase tumor uptake as well as reducing accumulation in kidneys Engineering solutions...

Molecular Partners AG (NASDAQ:MOLN – Get Free Report) saw a large growth in short interest in August. As of August 15th, there was short interest totalling 4,200 shares, a growth of 23.5% from the July 31st total of 3,400 shares. Based on an average daily volume of 2,000 shares, the short-interest ratio is presently 2.1 […]

RDT platform offers unique approach for tailored delivery of radioactive payloads to solid tumors RDT platform is focused on improving both...

Molecular Partners AG (NASDAQ:MOLN – Get Rating) was the target of a large decrease in short interest during the month of April. As of April 30th, there was short interest totalling 8,900 shares, a decrease of 60.4% from the April 15th total of 22,500 shares. Based on an average trading volume of 1,800 shares, the […]

Molecular Partners AG (NASDAQ:MOLN – Get Rating) saw a significant growth in short interest in April. As of April 15th, there was short interest totalling 22,500 shares, a growth of 9.2% from the March 31st total of 20,600 shares. Based on an average daily trading volume, of 2,200 shares, the short-interest ratio is presently 10.2 […]

Molecular Partners (NASDAQ:MOLN – Get Rating) and Quince Therapeutics (NASDAQ:QNCX – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, profitability, risk, analyst recommendations, dividends, earnings and institutional ownership. Profitability This table compares Molecular Partners and Quince Therapeutics’ […]